

# Hung Q Ly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11299049/publications.pdf>

Version: 2024-02-01

42  
papers

1,172  
citations

394421

19  
h-index

377865

34  
g-index

42  
all docs

42  
docs citations

42  
times ranked

2032  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Artificial Intelligence Applications in Cardiology: Current Landscape, Limitations, and the Road to Real-World Applications. <i>Journal of Cardiovascular Translational Research</i> , 2023, 16, 513-525.	2.4	5
2	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1994-2003.	2.8	96
3	Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada. <i>CJC Open</i> , 2021, 3, 1051-1059.	1.5	6
4	When the Complex Meets the High-Risk: Mechanical Cardiac Support Devices and Percutaneous Coronary Interventions in Severe Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 270-279.	1.7	4
5	Association Between Adherence to Fractional Flow Reserve Treatment Thresholds and Major Adverse Cardiac Events in Patients With Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2406.	7.4	30
6	Mesenchymal stem cell mediates cardiac repair through autocrine, paracrine and endocrine axes. <i>Journal of Translational Medicine</i> , 2020, 18, 336.	4.4	55
7	North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications. <i>American Heart Journal</i> , 2020, 227, 11-18.	2.7	33
8	Precautions and Procedures for Coronary and Structural Cardiac Interventions During the COVID-19 Pandemic: Guidance from Canadian Association of Interventional Cardiology. <i>Canadian Journal of Cardiology</i> , 2020, 36, 780-783.	1.7	61
9	Clinical outcomes of bioresorbable vascular scaffold to treat all-comer patients. Are patients with acute coronary syndrome better candidates for bioresorbable vascular scaffold?. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 228-234.	0.8	2
10	Surgical Turndown: "What" for Patients Deemed Ineligible for Surgical Revascularization. <i>Canadian Journal of Cardiology</i> , 2019, 35, 959-966.	1.7	7
11	The effect of bromocriptine on left ventricular functional recovery in peripartum cardiomyopathy: insights from the <sc>BRO</sc> retrospective cohort study. <i>ESC Heart Failure</i> , 2019, 6, 27-36.	3.1	30
12	Impact of summer season on pre-hospital time delays in women and men undergoing primary percutaneous coronary intervention. <i>Science of the Total Environment</i> , 2019, 656, 322-330.	8.0	8
13	Hockey Games and the Incidence of ST-Elevation Myocardial Infarction. <i>Canadian Journal of Cardiology</i> , 2018, 34, 744-751.	1.7	3
14	Long-term outcomes of bioresorbable vascular scaffold in ST-elevation myocardial infarction. <i>Acta Cardiologica</i> , 2018, 73, 276-281.	0.9	1
15	Weather and risk of ST-elevation myocardial infarction revisited: Impact on young women. <i>PLoS ONE</i> , 2018, 13, e0195602.	2.5	12
16	Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review. <i>Canadian Journal of Cardiology</i> , 2017, 33, 515-524.	1.7	9
17	Fractional flow reserve and resting indices for coronary physiologic assessment: Practical guide, tips, and tricks. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 598-611.	1.7	4
18	Collectively Operated Fellow-Initiated Research as a Novel Teaching Model to Bolster Interest and Increase Proficiency in Academic Research. <i>Canadian Journal of Cardiology</i> , 2017, 33, 685-687.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Giant aneurysm of a saphenous vein graft causing compression of cardiac structures in a patient with lung tumour: who is doing what?. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 113-113.	1.2	0
20	Bioresorbable vascular scaffold to treat in-stent restenosis: Single-center experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 558-563.	1.2	1
21	Everolimus-eluting bioresorbable vascular scaffold implantation to treat saphenous vein graft disease, single-center initial experience. <i>Journal of Interventional Cardiology</i> , 2017, 30, 433-439.	1.2	3
22	Prognostic impact of the residual <sc>SYNTAX</sc> score on in-hospital outcomes in patients undergoing primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 740-747.	1.7	22
23	Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	20
24	Epidemiology, Management Strategies, and Outcomes of Patients With Chronic Total Coronary Occlusion. <i>American Journal of Cardiology</i> , 2016, 118, 1128-1135.	1.6	106
25	Letter by Picard and Ly Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial"; <i>Circulation</i> , 2016, 133, e663.	1.6	0
26	Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies. <i>Canadian Journal of Cardiology</i> , 2016, 32, 247-255.	1.7	206
27	Letter by Azzalini and Ly Regarding Article, "The Learning Curve for Transradial Percutaneous Coronary Intervention among Operators in the United States: A Study from the National Cardiovascular Data Registry"; <i>Circulation</i> , 2015, 131, e357.	1.6	0
28	Direct Stenting Versus Pre-Dilation in ST-Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis. <i>Journal of Interventional Cardiology</i> , 2015, 28, 119-131.	1.2	26
29	Effect of Radial-to-Femoral Access Crossover on Adverse Outcomes in Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2014, 114, 1165-1173.	1.6	15
30	Transradial Percutaneous Coronary Interventions in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2014, 114, 160-168.	1.6	11
31	Nothing Refractory About Cardiac Cell Therapy. <i>Canadian Journal of Cardiology</i> , 2013, 29, 905-907.	1.7	0
32	The Paracrine Effect: Pivotal Mechanism in Cell-Based Cardiac Repair. <i>Journal of Cardiovascular Translational Research</i> , 2010, 3, 652-662.	2.4	34
33	In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction. <i>European Heart Journal</i> , 2009, 30, 2861-2868.	2.2	42
34	Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle. <i>Circulation</i> , 2009, 119, 1824-1831.	1.6	39
35	Advances in Gene-Based Therapy for Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2008, 1, 127-136.	2.4	9
36	Imaging in cardiac cell-based therapy: in vivo tracking of the biological fate of therapeutic cells. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2008, 5, S96-S102.	3.3	29

#	ARTICLE	IF	CITATIONS
37	In Vivo Tracking in Cardiac Stem Cell-Based Therapy. <i>Progress in Cardiovascular Diseases</i> , 2007, 49, 414-420.	3.1	56
38	Association of Platelet Counts on Presentation and Clinical Outcomes in ST-Elevation Myocardial Infarction (from the TIMI Trials). <i>American Journal of Cardiology</i> , 2006, 98, 1-5.	1.6	73
39	230. In Vivo Fluorescence Tracking System for Cardiac Stem Cell Therapy. <i>Molecular Therapy</i> , 2006, 13, S88.	8.2	1
40	Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2005, 95, 383-386.	1.6	21
41	A pilot study: The Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (The NICAMI Study). <i>American Heart Journal</i> , 2005, 150, 933.e9-933.e13.	2.7	71
42	Sudden death and hypertrophic cardiomyopathy: a review. <i>Canadian Journal of Cardiology</i> , 2005, 21, 441-8.	1.7	15